Details for Patent: 9,603,860
✉ Email this page to a colleague
Which drugs does patent 9,603,860 protect, and when does it expire?
Patent 9,603,860 protects DROSPIRENONE and SLYND and is included in two NDAs.
This patent has sixty-four patent family members in twenty-nine countries.
Summary for Patent: 9,603,860
| Title: | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| Abstract: | A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m.sup.2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration. |
| Inventor(s): | Perrin; Philippe (Paris, FR), Drouin; Dominique (Verrieres, FR), Boyer-Joubert; Cecile (Fontenay aux Roses, FR) |
| Assignee: | LABORATORIOS LEON FARMA SA (Navatejera Villaquilambre, ES) |
| Application Number: | 14/748,147 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,603,860 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,603,860
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ⤷ Try a Trial | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,603,860
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 081670 | ⤷ Try a Trial | |||
| Australia | 2011273605 | ⤷ Try a Trial | |||
| Brazil | 112012033391 | ⤷ Try a Trial | |||
| Brazil | 122019008317 | ⤷ Try a Trial | |||
| Canada | 2803721 | ⤷ Try a Trial | |||
| Canada | 3003062 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
